NASDAQIndustrialsIndustrial - MachinerySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for OFLX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain quarterly dividend of $0.34 per share | Omega Flex keeps paying a steady dividend of $0.34 per share each quarter. | Intact | dividend per share falls below $0.34 in any quarter | Dividend per share: $0.34 per share FY2026-Q3; GAAP. Published target: >= $0.34 per share quarterly. Target period is not explicitly aligned with this observation. Oct 30, 20260.34 USD/share · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 7–Nov 5 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a cyclical industrial business, meaning results can be affected by broader economic conditions. Its long-term thesis is in a watch state, with neutral readings on management, earnings quality, and recent performance, but elevated risk.
Valuation is broadly aligned with the model view and sits close to peer levels, with a small premium. Expectations appear broadly aligned rather than stretched, and the valuation measure has fallen notably in recent data; the evidence does not point to high fragility.
Near term, results may remain uneven: performance is below the industry cohort, and the company has a run of consecutive earnings misses, though the stated miss risk is low. Management has launched a re-engineered fitting and obtained a CE mark for MediTrac, while the financial impact of these milestones is not yet quantified; capacity and efficiency investments have also lacked specific delivery measures in the supplied figures.
Over the coming quarters, execution depends on whether product and certification milestones translate into measurable commercial progress and whether capacity investments produce clearer results. The sector backdrop could improve if industrial bellwethers continue to report strength, or worsen if they miss expectations; further labor-market weakness could also raise recession concerns for cyclical companies.
For the next one to three years, OFLX’s thesis rests on turning management’s stated priorities into measurable results while navigating sector headwinds and cyclical risk. Current evidence supports monitoring execution rather than treating the thesis as settled. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Omega Flex, Inc.'s published investment case. The stated target is >= -5% YoY revenue growth. |
| Under Pressure |
| revenue growth falls below -5% YoY next year |
Revenue growth: 6.04% FY2026-Q3; GAAP. Published target: >= -5% YoY revenue growth. Reported actuals cannot certify a consensus target without an explicit period and accounting-basis binding. Oct 30, 20266.036973 percent · calculatedLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain PE below peer median of 31.3 | A supporting condition in Omega Flex, Inc.'s published investment case. The stated target is <= 31.3 PE. | Intact | PE rises above 31.3 | P/E (TTM): 23.35x As of 2026-11-05; trailing twelve months. The target timing and basis require a separate assessment. Nov 5, 202623.3503 ratio · calculatedLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.